Utilizing MRI to Study the Effect of Sulforaphane on Prostate Cancer (ESCAPE-ING)
Effect of Sulforaphane on Prostate CAncer PrEvention-imagING Evaluation
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Terminated
Problems with recruitment
Other terminated trials from Cambridge University Hospitals NHS Foundation Trust
- Cogan Syndrome · Phase PHASE2 · Nov 2023
- Cardiovascular Diseases · Jun 2023
- Allograft · Phase NA · Apr 2023
- Antibody-mediated Rejection · Phase PHASE3 · Jan 2023
- Asthma · Apr 2020
See all terminations from Cambridge University Hospitals NHS Foundation Trust
Other Prostate Cancer trials with similar outcome
This NA trial investigates Prostate Cancer and is currently terminated or withdrawn. Cambridge University Hospitals NHS Foundation Trust leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Apr 2019 — Jan 2021 [monthly]
Terminated NA
-
Jun 2018 — Apr 2019 [monthly]
Terminated NA
▶ Show 2 earlier versions
-
Jun 2017 — Jun 2018 [monthly]
Terminated NA
-
Jan 2017 — Jun 2017 [monthly]
Terminated NA
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cambridge University Hospitals NHS Foundation Trust
- Quadram Institute Bioscience
For direct contact, visit the study record on ClinicalTrials.gov .